IGF1 and Alzheimer disease: Our findings reveal a pleiotropic role of low IGF1 expression in the pathogenesis of AD via MAPK, Ras, and FoxO signaling pathways, which may lead to a promising strategy in the prevention and treatment of AD by targeting IGF1.